Soluble-Mesothelin Related Peptide (SMRP) is a promising diagnostic biomarker for malignant pleural mesothelioma (MPM), but various confounders hamper its usefulness in surveillance programs. We previously showed that a single nucleotide polymorphism (SNP) within the 3'untranslated region (3'UTR) of mesothelin (MSLN) gene could affect the levels of SMRP. Here, we focused on SNPs located within MSLN promoter and found a strong association between serum SMRP and variant alleles of rs3764247, rs3764246 (that is in strong linkage disequilibrium with rs2235504), and rs2235503 in non-MPM subjects. The inclusion of the genotype information led to an increase in SMRP specificity from 79.9% to 85.5%. Although not statistically significant, the MPM population showed the same trend of association. In order to study the biological role of these SNPs, the promoter region of MSLN was cloned upstream a reporter gene and the four most common haplotypes were compared in a dual luciferase assay. Rs3764247 was shown to have a functional role itself. The other SNPs were shown to interact with each other in a more complex way. Altogether, these data support the idea that SMRP performance is affected by individual (i.e. genetic) variables and that MSLN expression is influenced by SNPs located within the promoter regulatory region. KEY WORDS: Malignant Pleural Mesothelioma, Single nucleotide polymorphism, solublemesothelin related peptide, promoter, biomarker specificity
INTRODUCTION
Mesothelin (MSLN) is a membrane-bound glycoprotein physiologically expressed by the mesothelial tissues of pleura, peritoneum, and pericardium (Hassan et al., 2004) . Although its biological function is still unknown (Bera and Pastan, 2000), many types of cancer, including malignant pleural mesothelioma (MPM), show increased expression of MSLN compared to their non-malignant counterparts (Hassan and Ho, 2008) . MPM is a highly aggressive tumor of the pleural cavities, associated with asbestos exposure and characterized by challenging diagnosis and poor prognosis (Panou et al., 2015) . In recent years, several research groups suggested that MSLN could be helpful in the management of MPM, both as diagnostic tool (Robinson et al., 2003; Cristaudo et., 2007) Thus, the inclusion of individuals' genetic information could improve the ROC curves calculation leading to slight improvements of the performance of SMRP as biomarker (Garritano et al., 2014) . Previously, studying a broad cohort of non-MPM subjects, we reported an association between serum SMRP levels and rs1057147, a single nucleotide polymorphism (SNP) located within the 3'untranslated region (3'UTR) of MSLN. This SNP lies within the binding site for miR-611, thereby affecting the post-transcriptional regulation of MSLN mRNA (Garritano et al., 2014) . Similarly, genetic variants located within the promoter region of MSLN were found to be associated with SMRP levels in a small group of non-MPM volunteers (Cristaudo et al., 2011) . Healthy subjects carrying the variant allele of rs3764247 A>C (reported as New1 in the original publication) showed increased SMRP levels compared to those carrying the AA genotype (Cristaudo et al., 2011) . This could be ascribed to a different regulatory pattern depending on the presence of the variant or common allele. In the present work we analysed a large sample set and we were able to replicate the association between rs3764247 and SMRP levels. Moreover, in order to further explore the role of genetic variants in MSLN/SMRP regulation, we (i) evaluated the association between SMRP and other SNPs located within the proximal MSLN promoter and (ii) performed an in vitro study to assess the biological role of the selected SNPs. Altogether, these findings could help to refine the use of SMRP as diagnostic biomarker and to shed some light in the regulatory mechanisms of MSLN gene.
MATERIALS AND METHODS

SNPs selection
In the pilot study, an association between rs3764247 and SMRP was found (Cristaudo et al., 2011) . Here, the association analysis was extended to other SNPs lying within the region of the proximal promoter of MSLN. Thus, selection criteria for the SNPs were: (i) to lie within 1000 bp (arbitrarily chosen) upstream the MSLN transcriptional start site (TSS); (ii) the frequency of the rare allele must be >0.05; (iii) to be reported as associated with MSLN mRNA expression in 278 lung tissue samples according to GTex portal (http://www.gtexportal.org/home/; Lonsdale et al., 2013) . The linkage disequilibrium (LD) between the selected SNPs (i.e. rs3764247 A>C, rs3764246 A>G, rs2235503 C>A, rs2235504 A>G) and the most common haplotypes was estimated with HaploView software version 4.2 (https://www.broadinstitute.org/.../haploview/haploview) using the TSI (Tuscans in Italy) population (however, CEU samples gave overlapping results).
Population description and genotyping
A total of 689 non-MPM subjects (healthy individuals n=371, or patients affected by benign respiratory diseases, BRDs, n=318) and 70 MPM volunteers were recruited at the University Hospital of Pisa as part of an occupational surveillance program on workers previously exposed to asbestos, as described in detail in Garritano et al., 2014 . Table 1 shows the clinical and demographic characteristics of the sample set. The study was approved by the institutional ethical committee of the University Hospital of Pisa. All subjects gave written informed consent. For genotyping, whole blood and serum samples were obtained by venipuncture and kept at -80°C until examination. DNA was extracted from whole blood samples using EuroGOLD Blood DNA Mini Kit (EuroClone, Pero, Italy). Genotyping of the three selected SNPs (i.e. rs3764247, rs3764246 and rs2235503) was performed using KASPar® PCR SNP genotyping system (LGC Genomics Ltd, Teddington, Middlesex, UK) with a success rate >96%. Allele frequencies (shown in Table 1 ) were in agreement with those reported in HapMap project for TSI (0.20, 0.25, and 0.15 for rs3764247, rs3764246 and rs2235503, respectively) and followed the Hardy-Weinberg equilibrium (P=0.753, P=0.583, and P=0.625, respectively). Serum SMRP levels were measured using an enzyme-linked immuno-sorbent assay according to the manufacturer's instructions (Mesomark, Fujirebio Diagnostics, Japan).
Association analyses between genotypes and SMRP levels
In order to verify the association between genotypes and serum SMRP levels, one-way analysis of variance (ANOVA) was performed, stratified for health status (healthy, BRD, MPM), for each SNP. Tukey's multiple comparison tests were performed to assess pairwise differences between the three genotypes within each group. In order to ascertain the global role of these SNPs in the association with SMRP in the different diagnostic groups, both the "non-MPM" (healthy subjects + BRD patients) and the MPM groups were stratified according to a three-SNPs classifier. According to this classifier, individuals carrying the common homozygote genotype for all the SNPs were considered as the reference category and were referred as carriers of the "L genotype" (L=low expression), whereas all the remaining subjects (i.e. carriers of at least one variant allele in one of the three SNPs) were considered to carry the "H genotype" (H=high). Then, a multivariate analysis of variance (mANOVA) was carried out to assess the association between SMRP values and L/H genotypes for each diagnostic group. The statistical significance threshold was set at 0.05 for all the analyses, which were performed using and StatGraphics Centurion XVI software (Manugistic, CA, USA).
Receiver Operating Characteristic (ROC) curves were generated with MedCalc statistical software (version 12.7.2.0, MedCalc Software, Belgium) comparing the non-MPM group versus the MPM group. First, the ROC curves were calculated without taking into account the genotypes. Then the curves were recalculated using SMRP levels of alternatively non-MPM volunteers carrying L or H genotype, versus the whole group of MPM patients (this group was not split in H/L genotype because no statistically significant differences were found in MPM patients).
Plasmids construction
The putative human MSLN promoter from nucleotides -1 to -1073 relative to the transcription start site was amplified by Q5® High-Fidelity DNA Polymerase (NEB, Ipswich, USA). As template, an individual carrying the common homozygote genotype for all the SNPs in study was selected from our sample set. The resultant polymerase chain reaction (PCR) amplicon was subsequently cloned into the XhoI site of the pGL3-basic vector (Promega, Madison, WI) using CloneEZ® PCR Cloning Kit (GenScript, Piscataway, USA). This construct, bearing the most common haplotype in the TSI population, is from now on referred as "pGL3_HAP1". Subsequent site-directed mutagenesis reactions were performed to generate the other haplotype-mimicking plasmids with QuikChange II Site-Directed Mutagenesis Kits (Agilent, Santa Clara, CA, USA). The fidelity of the resulting constructs (pGL3_HAP1/2/3/4) was confirmed by sequencing, using the pGL3 external primers (pGL3_F and pGL3_R). The sequence of cloning, mutagenesis, and sequencing primers are reported in Supplementary   Table 1 . 
Cell culture and luciferase reporter assays
Functional annotation of the SNPs of interest
To assess the possible functional role of the SNPs of interest, we used the ENCODE-based tool HaploReg v4 (www.broadinstitute.org/mammals/haploreg) and RegulomeDB (http://www.regulomedb.org/). Overall, SNPs were analysed for mapping within DNase I hypersensitive sites (DHSs), regulatory elements (enhancers and promoters), regulatory protein binding sites and altered motifs of transcription factors.
RESULTS
SNPs selection
In order to identify the genetic variants within MSLN proximal promoter (~1000 bp upstream to TSS) to be studied in association with SMRP, we searched for all SNPs significantly associated with MSLN mRNA expression in lung tissues on GTex portal (pleural tissues were unavailable). We found 86 cis-eQTLs with P-values ranging from 4.9x10 -6 to 4.4x10 -33 . The region spanning MSLN TSS shows the highest associated SNPs. Table 2 lists the top ten associated SNPs with their main features. Among the 86 associated SNPs, we selected those lying within the 1000 bp upstream to TSS, i.e. rs3764247 (16:g.810039 A>C), rs3764246 (16:g.810143 A>G), rs2235503 (16:g.810593 C>A), rs2235504 (16:g.810655 A>G). Since a strong LD (r 2 =0.94) was present between rs3764246 and rs2235504, we chose rs3764247, rs3764246 and rs2235503 for the genotyping analyses in association with SMRP.
Genotyping results in association with SMRP levels in healthy, BRD, and MPM subjects
As expected, the group of MPM patients showed a mean level of serum SMRP of 3.58 nM (±0.49, standard error of the mean SEM), significantly elevated (ANOVA, P<0.0001) when compared to the groups of healthy (0.94±0.03) or BRD (1.04±0.03) subjects. When the SMRP levels were analyzed in relation to genotypes for each SNP separately, a significant association (overall P-values calculated with ANOVA <0.0001) was found between SMRP and all the SNPs in the non-MPM category (healthy and BRD subjects). As it can be seen in Table 3 and in Figure 1 , for each SNP there is an increasing and statistically significant trend of SMRP levels in relation to the carried number of variant alleles. This trend was observed among healthy individuals as well as for BRD subjects, although the comparison between heterozygotes and variant homozygotes was not significant for rs3764247 and rs2235503 in the latter group. Interestingly, similar trends were also observed in the group of MPM patients, however no statistically significant differences were achieved for any of the SNPs (P = 0.166, 0.363 and 0.373 for rs3764247, rs3764246, and rs2235503, respectively).
In order to ascertain the global role of these SNPs, we used the three-SNPs classifier assigning the H or L genotype for each volunteer of this study. Then, a mANOVA was employed with "health status" and "classifier" as independent factors and this model confirmed that SMRP levels were associated with the promoter genotype (L vs H, P=0.001) and diagnosis (non-MPM vs MPM P <0.0001). Moreover, the interaction between these factors was not statistically significant (P=0.3730), given that also among MPM patients the group carrying the L genotype showed an average SMRP lower than the patients carrying the H genotype (however, the difference between H and L genotype within MPM patients was not statistically significant). 11 nM) , the AUC to 0.922, and the sensitivity and specificity to 83.6% and 85.5%, respectively. ROC curves calculated for non-MPM individuals with H-promoter showed a worse performance of SMRP, with AUC of 0.801 and a decrease of specificity to 67% in correspondence of Youden's J index (1.28 nM). Figure 2 A-B-C reports the discussed ROC curves, whereas Table 4 reports the punctual values of sensitivities and specificities for each group. The different cut-off values with their corresponding sensitivity and specificity for L and H groups are reported in Supplementary Table 2 and 3, for brevity.
In vitro study on the SNPs located within the MSLN promoter reported a functional role for rs3764247
In order to elucidate the biological role of the SNPs found to be associated with SMRP, an in vitro study was performed cloning the putative promoter region of MSLN upstream to a reporter gene. We then applied site-directed mutagenesis to obtain the most common haplotypes present in the population (i.e. pGL3_HAP1 A-A-C-A; pGL3_HAP2 C-G-A-G; pGL3_HAP3 A-G-C-G; pGL3_HAP4 C-A-C-A). Since the strongest association between genotype and SMRP was found among non-MPM individuals, we employed Met-5A cells as a model of non-MPM tissue. The vectors were transfected into these cells and the reporter activity under the control of promoters bearing different genetics variants was evaluated. A significant difference in RLU (overall P-value calculated with ANOVA <0.0001) was found among the constructs. When compared to pGL3_HAP1 (artificially set at 100%, ± 4% SEM), RLU values of pGL3_HAP2, pGL3_HAP3 and pGL3_HAP4 were 121% (±8%), 97% (±12%) and 182% (±18%), respectively. The pairwise comparisons revealed that the difference between pGL3_HAP1 and pGL3_HAP4 was statistically significant, as shown in Figure 3 , whereas that between pGL3_HAP1 and pGL3_HAP2 is close to the statistical significance (P=0.064).
Functional annotation of the SNPs of interest
According to luciferase assay results, rs3764247 seemed to play a direct role in the regulation of the MSLN gene. HaploReg v4 showed that this SNP is located in DNase I hypersensitive sites (DHSs) in neuronal progenitors and astrocyte primary cells. According to RegulomeDB, it lies within enhancer regions in lung tissues and it is suggested to affect binding sites for two transcription factors, namely Staf and ZNF143. As pGL3_HAP3 did not show any difference in luciferase activity when compared to pGL3_HAP1, we could conclude that rs3764246 and rs2235504 did not exert a direct functional role in the regulation of MSLN.
Nonetheless, rs2235505, located in the second intron of the MSLN gene, shows a very high LD with these SNPs (r 2 >0.9). Thus, we analyzed the functional annotation available about rs2235505 in HaploReg and RegulomeDB database. It was reported to be located in DHSs in HeLa and HepG2 cell lines and to affect several transcription factor binding motifs such as BHLHE40, CTCF, PLAG1 and Rad21. It was also shown to bind RCOR1 chromatin binding protein in HeLa cells. No alteration in the splicing mechanism was predicted by SpliceAid software. A visual summary of the results of the functional study on the MSLN promoter is reported in Figure 4 .
DISCUSSION
MSLN is a membrane glycoprotein described as functionally involved in many malignancies, including MPM. It has been repeatedly reported that the measurement of the levels of its (Singh et al., 2013) . In the present study, we were aimed to broaden the knowledge about the biological role played by genetic variants located within MSLN promoter region with potential impact also on the performance of SMRP as diagnostic biomarker. Thus, we selected four SNPs (rs3764247 A>C, rs3764246 A>G, rs2235503 C>A, rs2235504 A>G) within 1000 bp upstream the MSLN TSS and, in the first part of the study, we investigated the association between SMRP and genetic variants in over 700 individuals, awarding reliability against possible chance findings. We found associations between genotypes and SMRP levels among non-MPM individuals, in agreement with those reported in the cis-eQTL database within GTex portal. and pGL3_HAP4 in the present study. However, a direct effect of rs3764247 was suggested by the higher expression of pGL3_HAP4 when compared to pGL3_HAP1, and further studies are needed in order to ascertain its role in MSLN regulation. For instance, it is reported to affect the binding sites of transcription factors such as Staf or ZNF143, thus future research could be directed towards the experimental validation of this interaction in mesothelial cells. Moreover, according to the luciferase assay, rs3764246 and rs2235504 are unlikely to play a direct role in MSLN regulation, as suggested by the similar expression of pGL3_HAP3 and pGL3_HAP1. However, rs2235505, which is located within intron 2 of MSLN, is in strong LD with them and it could be responsible for the differential levels of SMRP found in our association study. This SNP is also included in the list of associated SNPs in cis-eQTL database and functional annotations reported several transcription factorbinding sites affected by its variant allele. Thus, rs2235505 could be worth of further investigations including an in vitro functional study with a similar approach to the one performed here. Interestingly, our results are reminiscent of previous observations concerning SNPs lying within the PSA (prostate-specific antigen) gene promoter (Cramer et al., 2008) . In fact, these SNPs were shown to contribute to individual differences among healthy men in the levels of serum PSA, a common biomarker for prostate cancer (Cramer et al., 2008) . This reinforces the notion of implementing the genetic information when considering specific biomarkers in surveillance programs. Interestingly, we noticed that, similarly to what observed in non-MPM volunteers, among MPM patients rare homozygotes had the highest average levels of SMRP, whereas heterozygotes showed intermediate levels. However, these trends, as well as the difference between H and L genotypes, were not statistically significant.
We hypothesize that the lack of statistical significance has to be ascribed to the relative small number of MPM patients recruited in this study. We could not collect more patients, being MPM a rare disease, however it is likely that also among patients the increase of SMRP could be more evident among carriers of the H genotype.
In conclusion, we reported that SMRP levels are affected by genetic variants, with the consequence of suggesting different "warning" thresholds for healthy subjects carrying 
